Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure

Kimmenade, Roland R.J. van; Januzzi, James L.; Ellinor, Patrick T.; Sharma, Umesh C; Bakker, J.; Low, Adrian F.; Martinez, A. Canton; Crijns, Harry J.G.M.; MacRae, Calum A.; Menheere, P. P. C. A.; Pinto, Yigal M.

doi:10.1016/j.jacc.2006.03.061

Cited by 525 publications

(405 citation statements)

References 44 publications

Supporting

Mentioning

351

Contrasting

Unclassified

Order By: Relevance

“…Recent studies have revealed that Gal-3 appears to be a promising prognostic biomarker in HF patients [3,6,7,21,23,24]. In our study, patients who died during the follow-up period presented significantly higher baseline Gal-3 levels than the survivors, which is in line with some previous reports [3,6,7,21,23,24].…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Galectin-3 in Patients with Acute Heart Failure: Preliminary Report on First Polish Experience

Sygitowicz¹,

Tomaniak²,

Filipiak‬³

et al. 2016

Adv Clin Exp Med

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

“…Our preliminary study demonstrated that, among patients with AHF hospitalized in the tertiary care center, the plasma levels of Gal-3 were significantly elevated in comparison with controls without AHF, which is in line with some experimental and clinical studies [3][4][5][6]19].…”

Section: Discussionsupporting

confidence: 89%

Galectin-3 in Patients with Acute Heart Failure: Preliminary Report on First Polish Experience

Sygitowicz¹,

Tomaniak²,

Filipiak‬³

et al. 2016

Adv Clin Exp Med

View full text Add to dashboard Cite

“…возрастание уровня галектина-3 коррелировало с возрастом пациентов, ухуд-шением функции почек, тяжестью ХСН. [15] В нашей работе медиана галектина-3 была связана со стадией ХСН ФК NYHA (p<0,05). Уровень галектина-3 в плазме крови больных в группе пациентов с ХСН ФК II NYHA составил 6,85 [3,67; 10,02] нг / мл, в группе пациентов с ХСН ФК III NYHA -9,61 [7,75; 12,6] нг / мл.…”

Section: Discussionunclassified

“…Данные уровни сопоставимы со средней концентрацией этого биомаркера у пациентов с острой СН в других исследованиях [15,16].…”

Section: Discussionunclassified

New possibilities of diagnostics and control of efficacy of drug therapy for chronic heart failure

Gyamdzhyan¹,

Кукес²

2017

RHFJ

View full text Add to dashboard Cite

В настоящее время только BNP и NT-proBNP рекомен-дованы для использования в качестве биомаркеров для диагностики, мониторинга и оптимизации фармако-терапии пациентов ХСН. Известно, что основным тригге-ром для продукции натрийуретических пептидов являет-ся натяжение стенки миокарда ЛЖ в ответ на перегрузку объе мом. Однако, кроме напряжения стенки миокарда, в патогенезе ХСН также принимают участие и другие про-цессы, такие как воспаление и фиброз. Натрийуретические пептиды не дают возможности оценивать выраженность данных процессов, в связи с чем поиск биомаркеров фиброза и воспаления является актуальным.В исследованиях DEAL-HF и СOACH была продемон-стрирована способность нового биомаркера галектина-3 отражать процессы воспаления и фиброза, лежащих в осно-ве ремоделирования миокарда у пациентов с ХСН [1][2][3].Галектин-3 принадлежит к семейству β-галактозид-связывающих протеинов. Благодаря наличию в своей Гямджян К. А., Кукес В. Г. p=0.02). No significant correlation was found with other clinical indexes, such as systolic BP, diastolic BP, heart rate, BMI, 6-min walk test, left ventricular myocardial mass index, glucose concentration, total cholesterol, and GFR. A moderate correlation was observed for levels of NT-proBNP and plasma galectin-3 (r=0.3; p=0.02). Post-treatment decreases in galectin-3 were observed in 84.3% patients. Conclusion. Galectin-3 can be used as an auxiliary diagnostic biomarker for CHF.

show abstract

“…Given NT‐proBNP's strong associations with heart failure, mortality attributable to cardiovascular events, and mortality after cardiac surgery, its inclusion in a prediction model of in‐hospital mortality may serve to improve the model's predictive ability 13, 14, 15, 16. Galectin‐3, a member of the lectin family of proteins, and ST2, a biomarker for cardiac stress, have also been found to be strongly associated with heart failure 17, 18, 19, 20, 21, 22. Additionally, Galectin‐3 has been found to be associated with increased risk for all‐cause mortality in the Framingham Offspring Cohort 23.…”

Section: Introductionmentioning

confidence: 99%

Predictive Ability of Novel Cardiac Biomarkers ST2, Galectin‐3, and NT‐ProBNP Before Cardiac Surgery

Polineni

Parker

Alam

et al. 2018

JAHA

View full text Add to dashboard Cite

BackgroundCurrent preoperative models use clinical risk factors alone in estimating risk of in‐hospital mortality following cardiac surgery. However, novel biomarkers now exist to potentially improve preoperative prediction models. An assessment of Galectin‐3, N‐terminal pro b‐type natriuretic peptide (NT‐ProBNP), and soluble ST2 to improve the predictive ability of an existing prediction model of in‐hospital mortality may improve our capacity to risk‐stratify patients before surgery.Methods and ResultsWe measured preoperative biomarkers in the NNECDSG (Northern New England Cardiovascular Disease Study Group), a prospective cohort of 1554 patients undergoing coronary artery bypass graft surgery. Exposures of interest were preoperative levels of galectin‐3, NT‐ProBNP, and ST2. In‐hospital mortality and adverse events occurring after coronary artery bypass graft were the outcomes. After adjustment, NT‐ProBNP and ST2 showed a statistically significant association with both their median and third tercile categories with NT‐ProBNP odds ratios of 2.89 (95% confidence interval [CI]: 1.04–8.05) and 5.43 (95% CI: 1.21–24.44) and ST2 odds ratios of 3.96 (95% CI: 1.60–9.82) and 3.21 (95% CI: 1.17–8.80), respectively. The model receiver operating characteristic score of the base prediction model (0.80 [95% CI: 0.72–0.89]) varied significantly from the new multi‐marker model (0.85 [95% CI: 0.79–0.91]). Compared with the Northern New England (NNE) model alone, the full prediction model with biomarkers NT‐proBNP and ST2 shows significant improvement in model classification of in‐hospital mortality.ConclusionsThis study demonstrates a significant improvement of preoperative prediction of in‐hospital mortality in patients undergoing coronary artery bypass graft and suggests that biomarkers can be used to identify patients at higher risk.

show abstract

Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure

Cited by 525 publications

References 44 publications

Galectin-3 in Patients with Acute Heart Failure: Preliminary Report on First Polish Experience

Galectin-3 in Patients with Acute Heart Failure: Preliminary Report on First Polish Experience

New possibilities of diagnostics and control of efficacy of drug therapy for chronic heart failure

Predictive Ability of Novel Cardiac Biomarkers ST2, Galectin‐3, and NT‐ProBNP Before Cardiac Surgery

Contact Info

Product

Resources

About